on GENFIT (EPA:GNFT)
GENFIT is included in the CAC Mid 60 and SBF 120 indices
GENFIT, a biopharmaceutical company specializing in rare liver diseases, announces its inclusion in the CAC Mid 60 and SBF 120 indices of Euronext Paris from September 18, 2026. This ranking is the result of the annual review by the Scientific Council of Indices.
The decision to include GENFIT in these indices reflects an increase in its market capitalization and liquidity, thereby improving its visibility among institutional investors. Pascal Prigent, CEO of GENFIT, states that this development confirms investors' confidence in the company's strategy and its ability to innovate for patients.
The SBF 120 and CAC Mid 60 indices are important benchmarks at Euronext Paris, comprising respectively 120 major stocks and mid-sized companies.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all GENFIT news